OS Therapies (OSTX) Income towards Parent Company (2023 - 2026)

OS Therapies (OSTX) has 4 years of Income towards Parent Company data on file, last reported at -$10.3 million in Q1 2026.

• Quarterly Income towards Parent Company fell 106.45% year-over-year to -$10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.4 million (down 193.76% YoY) and the FY2025 annual result came in at -$30.2 million, down 97.05% from the prior year.
• Income towards Parent Company rose to -$10.3 million in Q1 2026, from -$13.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$1.5 million in Q4 2023 to a low of -$13.5 million in Q4 2025.
• A 4-year average of -$4.5 million and a median of -$2.9 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 37.83% — and 2025, when it sank 352.62%.
• Tracing OSTX's Income towards Parent Company over 4 years: stood at -$1.5 million in 2023, then slumped by 103.06% to -$3.0 million in 2024, then slumped by 352.62% to -$13.5 million in 2025, then grew by 23.32% to -$10.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$10.3 million (Q1 2026), -$13.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.